Sequential Lenvatinib
Phase 3Small molecule
Sequential Lenvatinib is one of 76 small molecule programs targeting Classic Hodgkin Lymphoma. It is currently in Phase 3.
2
Indications
3
Total Trials
2
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
175 competitors in Polycystic Ovary Syndrome
#DrugCompanyPhaseTrials
1DLBS3233
DDexa Medica Group
Phase 3
Sequential Lenvatinib
SSun Yat-sen University
Phase 3
Oral Contraceptive Pills
SSheba Medical Center
Phase 3
Clomid
FerringPreclinical
Precose
BayerPreclinical
Proglycem
TevaPreclinical
Cetrotide
EMD SeronoPreclinical
Clomid
EMD SeronoPreclinical
Casodex
IIstituto Clinico Humanitas
Preclinical
Trelstar
OOncoVerity, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Classic Hodgkin Lymphoma1 trial
Polycystic Ovary Syndrome1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sequential Lenvatinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSun Yat-sen University